Hematology

Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

New ASH guidelines recommend higher ferritin thresholds to improve the diagnosis of iron deficiency across key populations.

A pediatric hematologist unpacks why sickle cell disease burden, treatment access, and pain outcomes differ across sub-Saharan Africa, other LMICs, and HICs.

Stacey Rifkin-Zenenberg, DO, marks Sickle Cell Disease Awareness Month with insight on gene therapy vs. transplant.

A phase 2 study found the EAP regimen achieved optimal stem cell mobilization in most patients with multiple myeloma or lymphoma, with low plerixafor need.

Nipocalimab-aahu (IMAAVY) is now approved for wAIHA, based on Phase 2/3 ENERGY trial data showing durable hemoglobin response.

New research links germline genetic variants to CAR T cell toxicity risk and expansion in lymphoma patients treated with axi-cel.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

Agios ends tebapivat development in sickle cell disease after phase 2 results show no differentiated benefit.

Wendy Stock, MD, on the recent FDA approval of Orca-T, a precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies

FDA grants Priority Review to Agios’ mitapivat sNDA for sickle cell disease, with a PDUFA date set for November 1, 2026.

Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Catch up on the hematology news and data you missed from April 2026.

Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities.

Study investigator Inusa explains the gap in sickle cell disease findings from SWAP, a multinational survey.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Hanna explains the real-world barriers to implementing gene editing therapies in sickle cell disease.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy.

Hanna, MD, shares results from reni-cel, a one-time gene editing therapy for patients with sickle cell disease.